Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

The Global Market for Cancer Immunotherapy - Forecast to 2024: Monoclonal Antibodies, Checkpoint Inhibitors, Immunomodulators, Vaccines, Cell Therapy - ResearchAndMarkets.com

Research and Markets
Posted on: 08 Nov 18

The "Cancer Immunotherapy Market By Type (Monoclonal Antibodies, Checkpoint Inhibitors, Immunomodulators, Vaccines, Cell Therapy), Application (Lung, Breast, Multiple Myeloma, Colorectal, Melanoma, Prostate), And End User- Global Forecast To 2024" report has been added to ResearchAndMarkets.com's offering.

The global cancer immunotherapy market is expected to grow at a CAGR of 13.8% from 2018 to reach USD 152.83 billion by 2024.

The high growth of cancer immunotherapy market is attributed to factors such as rising incidence of cancer globally, rising adoption of cancer immunotherapies over other conventional cancer treatments owing to the increased survival rate and less side effects with immunotherapy drugs, increasing number of ongoing clinical trials with the help of rising investments by major players in the market, and development of bioinformatics tools that are enhancing the drug development process for cancer immunotherapy market.

However, the high cost of the cancer immunotherapy treatment is restricting the growth of this market to some extent. Apart from this, growing R&D investments by major players in the market to develop cancer immunotherapies and high growth prospects in the developing countries such as China and India provides significant opportunity in this market.

Monoclonal antibodies dominated the global cancer immunotherapy market, mainly due to their high adoption for cancer treatment, rising number of US FDA approvals, and better five-year survival rates as compared to other cancer treatment options available in the market.

Cancer immunotherapy market for lung cancer application commanded the largest share, mainly attributed to increasing incidence of lung cancer, the significant benefit of cancer immunotherapy for lung cancer compared with other treatment options, and rising adoption of immunotherapies in lung cancer owing to the higher survival rate.

Market Dynamics

Drivers

  • Rising Cancer Incidence
  • Growing Adoption of Immunotherapy over other Treatment Options
  • Increasing Number of Technological Collaborations and Mergers
  • Development of Bioinformatics Tools Enhancing Drug Development Process

Restraints

  • High Cost of Treatment

Opportunities

  • Growing R&D Expenditure
  • High Growth Prospects in Emerging Economies

Challenges

  • Limited Funds with Small and Mid-Sized Organizations to Initiate the Clinical Trials
  • Complexities of Tumor

Key Topics Covered

1. Introduction

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Industry Insights

6. Cancer Immunotherapy Market, by Type

7. Cancer Immunotherapy Market, by Application

8. Cancer Immunotherapy Market, by End-User

9. Cancer Immunotherapy Market, by Region

10. Competitive Landscape

11. Company Profiles

  • Amgen Inc.
  • Bayer
  • Bristol-Myers Squibb
  • Celgene Corporation
  • Dendreon Pharmaceuticals
  • Eli Lilly and Company
  • F. Hoffmann-La Roche
  • Gilead Sciences Inc.
  • Janssen Global Services LLC
  • Merck & Co. Inc.
  • Novartis
  • Pfizer Inc.

For more information about this report visit https://www.researchandmarkets.com/research/ssxbrz/the_global_market?w=4

View source version on businesswire.com: https://www.businesswire.com/news/home/20181108005637/en/

Business Wire
www.businesswire.com

Last updated on: 08/11/2018

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.